Companies › PureTech
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Respiratory; next expected readout Nov 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Deupirfenidone (LYT-100) Deuterated pirfenidone analogue; antifibrotic agent | – | Phase 3 | Idiopathic Pulmonary Fibrosis (IPF); Idiopathic Pulmonary Fibrosis | Nov 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05321420 | Deupirfenidone (LYT-100) | Phase 2 | Idiopathic Pulmonary Fibrosis | Respiratory | Oct 2024 |
| NCT07284602 | Deupirfenidone (LYT-100) | Phase 3 | Idiopathic Pulmonary Fibrosis (IPF) | Respiratory | Nov 2029 |
No annotated target.
–
Biotest Areteia Therapeutics Renovion Youssef Yammine Kringle Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.